Hematology/Oncology

Top Story

FDA grants breakthrough therapy designation to Azedra for pheochromocytoma, paraganglioma

July 28, 2015

The FDA granted breakthrough therapy designation to Ultratrace iobenguane I-131 for the treatment of patients with iobenguane-avid metastatic or recurrent pheochromocytoma and paraganglioma, according to a press release from the drug’s manufacturer.

Ultratrace iobenguane I-131 (Azedra, Progenics Pharma), a late-state radiotherapeutic drug candidate, is being evaluated in a phase 2b trial of patients with malignant pheochromocytoma or paraganglioma. Pheochromocytomas — rare tumors usually found within one or both adrenal glands — are referred to as paragangliomas when they arise in other areas of sympathetic nerve cells.

Takashi Nojiri In the Journals

Low-dose olprinone reduces risk for atrial fibrillation after lung cancer surgery

July 28, 2015
The administration of olprinone continuously during lung cancer surgery reduced the risk for atrial fibrillation in patients with elevated preoperative B-type…
In the Journals

Combination of cladribine, cytarabine improves survival for children with LCH

July 28, 2015
The combination of cladribine and cytarabine conferred high survival rates among children with high-risk, risk organ-positive Langerhans cell histiocytosis, according to…
In the Journals

Ethanol locks reduce central venous catheter-associated bloodstream infections in children with cancer

July 27, 2015
Ethanol locks prevented central venous catheter-associated bloodstream infections in pediatric patients with cancer, according to the results of a randomized…
In the Journals

Tivantinib, erlotinib improve PFS, not OS in advanced NSCLC

July 27, 2015
The addition of tivantinib to erlotinib did not improve OS in patients with advanced or metastatic nonsquamous non–small cell lung cancer, according to results of…
More News Headlines »
Tailored Therapies for Myelodysplastic Syndromes

Tailored Therapies for Myelodysplastic Syndromes

This activity is supported by an educational grant from Celgene Corporation.

Myelodysplastic syndromes (MDS) represent a group of myeloid clonal hemopathies with heterogeneous clinical…
More »
Meeting News Coverage Video
VIDEO: 'Care paths' may help manage rising cancer costs

VIDEO: 'Care paths' may help manage rising cancer costs

June 19, 2015
CHICAGO — Brian Bolwell, MD, chairman of Taussig Cancer Institute at Cleveland Clinic, discusses an abstract on…
More »
CME
Hematology Oncology Case Consults

The Patient with Chronic Lymphocytic Leukemia

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with chronic lymphocytic leukemia.
More »
morganatic-roan